Strengthening the reporting of genetic risk prediction studies: The GRIPS statement

Circulation: Cardiovascular Genetics

Volumn 4, Issue 2, 2011, Pages 206-209

  Janssens, A Cecile J W ^a,f   Ioannidis, John P A ^b,c,d,e   Van Duijn, Cornelia M ^a   Little, Julian ^g   Khoury, Muin J ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENETIC RISK; GENETIC VARIABILITY; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC RESEARCH; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 79959720729     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.111.959668     Document Type: Article

References (25)

1. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007;9:665-674. (Pubitemid 350287151)
2. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-2416.
3. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007;99:236-243.
4. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005;97:1043-1055. (Pubitemid 41417921)
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2:416-422. (Pubitemid 43115010)
6. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer. 2007;43:2559-2579. (Pubitemid 350086938)
7. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009; 302:2345-2352.
8. von Elm E, Egger M. The scandal of poor epidemiological research. BMJ. 2004;329:868-869. (Pubitemid 39422927)
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40:35-53.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296. doi:10.1371/journal.pmed.0040296. (Pubitemid 350035453)
11. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009;6:e22. doi: 10.1371/journal.pmed.1000022.
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003;326:41-44. (Pubitemid 36110721)
13. Janssens ACJW, Van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med. 2009;1:20.
14. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol. 2010;172:517-524.
15. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ. 2009;338:b606.
16. Khoury MJ, Dorman JS. The Human Genome Epidemiology Network. Am J Epidemiol. 1998;148:1-3. (Pubitemid 28317537)
17. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97:715-723. (Pubitemid 40872378)
18. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-694. (Pubitemid 32322245)
19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1-W12.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. doi:10.1371/journal.pmed.1000100.
21. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. doi:10.1371/journal.pmed. 0040297. (Pubitemid 350035454)
22. Vandenbroucke JP. STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK and CONSORT: for whom does the guideline toll? J Clin Epidemiol. 2009;62: 594-596.
23. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935. (Pubitemid 46294733)
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172. (Pubitemid 351193639)
25. Janssens ACJW, Khoury MJ. Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference? Circ: Cardiovasc Genet. 2010;3:3-5.